NCT06036745View on ClinicalTrials.gov

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 1, 2023

Study Completion Date

July 1, 2026

Conditions
Gastric Cancer Stage IIIB-IIIC
Interventions
DRUG

Pembrolizumab + SOX

Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Minimally Invasive Surgery Center

OTHER